Thomas Kowalkowski, MD
Urology · Ronceverte, WVNPI 1942296066
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Astellas Pharma US Inc at 39.6% of the total. That places this record below the midpoint for urology clinicians in WV, where the typical reported total is $2,534.
Across 165 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$961
- Pfizer$436
- Axonics, Inc.$165
- Urovant Sciences Inc$126
- Sumitomo Pharma America, Inc.$126
- AbbVie$79
- plus $534 from 16 others
What the payments were for
- Food & beverage$2,38398%
- Education$432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 75 | $961 |
| Pfizer | 33 | $436 |
| Axonics, Inc. | 8 | $165 |
| Urovant Sciences Inc | 7 | $126 |
| Sumitomo Pharma America, Inc. | 6 | $126 |
| AbbVie(2 entities) | 5 | $79 |
| Teleflex LLC | 3 | $63 |
| Bayer | 4 | $59 |
| Johnson & Johnson | 3 | $56 |
| Boston Scientific | 3 | $48 |
| Endo Pharmaceuticals Inc. | 3 | $47 |
| Merck | 3 | $43 |
| Urogen Pharma, Inc. | 2 | $34 |
| Coloplast | 1 | $28 |
| Hollister Incorporated | 2 | $26 |
| Laborie Medical Technologies Corp. | 1 | $24 |
| Telix Pharmaceuticals | 1 | $24 |
| Novartis | 1 | $22 |
| Novo Nordisk | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $12 |
| Blue Earth Diagnostics | 1 | $11 |
How this compares
$2,426 in reported general payments places this provider in the 45th percentile of 67 urology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $193,930 |
| MyrbetriqMirabegron | 99 | $96,127 |
| ElmironPentosan Polysulfate Sodium | 34 | $35,422 |
| Trimethoprim | 522 | $32,553 |
| Tamsulosin Hcl | 1,604 | $21,996 |
| Finasteride | 1,510 | $18,884 |
| GemtesaVibegron | 27 | $18,508 |
| Minocycline Hcl | 482 | $10,464 |
| Oxybutynin Chloride ErOxybutynin Chloride | 469 | $9,749 |
| Solifenacin Succinate | 139 | $6,659 |
| Silodosin | 84 | $6,572 |
| Dutasteride | 114 | $3,838 |
| Trospium Chloride | 33 | $3,708 |
| Doxazosin Mesylate | 224 | $3,303 |
| ToviazFesoterodine Fumarate | 11 | $3,001 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $961 | $290,057113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $126 | $18,50827 claims |
| PfizerToviaz, Premarin | $436 | $5,73223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 67 urology providers in West Virginia.
Other urology in Ronceverte
- Kyle FortRonceverte$6K
- Joseph MouchizadehRonceverte$4K
- Jaschar Shakuri-RadMorgantown$77K
- Ali HajiranMorgantown$37K
- Lynnetta PayneBeckley$23K
- Stanley ZaslauHuntington$14K
- John BarnardMorgantown$10K
- Mohamad SalkiniMorgantown$8K
- Joshua LohriCharleston$8K
- Nathan HaleCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.